Canadian regulators approved GlaxoSmithKline’s Shingrix vaccine for treatment of shingles in adults 50 and over.
An FDA advisory committee endorsed Shingrix for the same indication in September. The FDA has not acted on the pending application for approval of Shingrix.
Shingrix is a non-live, recombinant subunit vaccine for shingles and its complications, such as postherpetic neuralgia.
Merck’s Zostavax is the only FDA-approved shingles vaccine.